Nakano T, Shimanuki T, Matsushita M, Koyama I, Inoue I, Katayama S, David H.
Alpers, Komoda T : Involvement of intestinal alkaline phosphatase in serum
apolipoprotein B-48 level and its association with ABO and secretor blood group types.
Biochem Biophys Res Commun 341(1):33-38, 2006.
2006
Uno K, Katagiri H, Yamada T, Ogihara T, Imai J, Hasegawa Y, Gao J, Kaneko K, Iwasaki H,
Ishihara H, Sasano H, Inukai K, Mizuguchi H, Asano T, Shiota M, Nakazato M, Oka Y, Neuronal
pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science
312(5780), 1656-1659, 2006
2006
Haller H, Viberti GC, Mimran A, Remuzzi A, Rabelink AJ, Ritz E, Rump LC, Ruilope
LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz : Preventing microalbuminuria in
patients with diabetes: rationale and design of the Randomised Olmesartan and
Diabetes Microalbuminuria Prevention (ROADMAP)study . J Hypertens. 24(2):
403-8, 2006.
2006
Tsurumaru M, Kawasaki E, Ida H, Migita K, Moriuchi A, Fukushima K, Fukushima T,
Abiru N, Yamasaki H, Noso S, Ikegami H, Awata T, Sasaki H, Eguchi K
Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus
in the Japanese population. J Clin Endocrinol Metab. 91(8):3138-31432006.
2005
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, and
Katayama S : The Telmisartan Renoprotective Study from Incipient Nephropathy to
Overt Nephropathy – Rationale,Study Design ,Treatment Plan and Baseline
Characteristics of the Incipient to Overt:Angiotensin
Receptor Blocker,Telmisartan, Investigation on Type 2 Diabetic Nephropathy
(INNOVATION)study. The Journal of International Medical Research 33(6) :
677-686,2005.
2005
Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH : A peroxisome proliferator-activated receptor- agonist reduces infarct size in transient but not in permanent ischemia. Stroke 368(2):353-359,2005
2005
Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, Katayama S,
Saito Y, Ito H, Ohashi Y, Akanuma Y, Yamada N : Is the Diagnosis of Metabolic
Syndrome Useful for Predicting Cardiovascular Disease in Asian Diabetic Patients? .
Diabetes Care 28(6): 1463-1469, 2005.
2005
Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama I, Sawa T, Kurihara S,
Awata T, Katayama S : Glimepiride enhances intrinsic peroxisome
proliderator-activated receptor – activity in 3T3-L1 adipocytes.
Biochem Biophys Res Commun 328:484-490,2005.
2005
Inukai K, Awata T, Inoue K, Kurihara S, Nakashima Y, Watanabe M, Sawa T, Takata
N, Katayama S : Identification of a novel WFS1 mutation (AFF344-345ins) in Japaness
patirnts with Wolfram syndrome. Diabetes Res and Clin Pract 69:136-141, 2005.
2005
Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, Osaki M, Watanabe M,
Nakashima Y, Inukai K, Inoue I, Kawasaki I, Mori K, Yoneya S, Katayama S :
Functional VEGT C-634G polymorphism is associated with development of diabetic
macular edema and correlated with macular retinal thickness in type 2 diabetes.
Biochem Biophys Rese Commun. 333:679-685, 2005.
2005
Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S,
Awata T, Katayama S: Glimepiride enhances intrinsic peroxisome
proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem
Biophys Res Commun. 2005;328:484-90.
2005
Kushiyama A, Shojima N, Ogihara T, Inukai K, Sakoda H, Fujishiro M, Fukushima Y,
Anai M, Ono H, Horike N, Viana AY, Uchijima Y, Nishiyama K, Shimosawa T, Fujita
T, Katagiri H, Oka Y, Kurihara H, Asano T: Resistin like molecule beta activates
MAPKs, suppresses insulin signaling in hepatocytes and induces diabetes,
hyperlipidemia and fatty liver in transgenic mice on a high-fat diet. J Biol Chem.
280(51), 42016-42025, 2005
2005
Shojima N, Ogihara T, Inukai K, Fujishiro M, Sakoda H, Kushiyama A, Katagiri H, Anai M, Ono H,
Fukushima Y, Horike N, Viana AY, Uchijima Y, Kurihara H, Asano T, Serum concentrations of
resistin-like molecules beta and gamma are elevated in high-fat-fed and obese db/db mice, with
increased production in the intestinal tract and bone marrow. Diabetologia 48, 984-992, 2005
2005
Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K,
Suzuki M, Kurihara S, Awata T, Katayama S: Efficacy of Glimepiride in Japanese Type 2 Diabetic
Subjects. Diabetes Res. Clin. Pract. 68, 250-257, 2005
2005
Inukai K, Nakashima Y, Watanabe M, Takata N, Sawa T, Kurihara S, Awata T,
Katayama S:]Regulation of adiponectin receptor gene expression in diabetic mice. Am. J.
Physiol. Endocrinol. Metab. 288, E876-882, 2005
2005
Iwasaki N, Horikawa Y, Tsuchiya T, Kitamura Y, Nakamura T, Tanizawa Y, OkaY,
Hara K, Kadowaki T, Awata T, Honda M, Yamashita K, Oda N, Yu L, Yamada N,
Ogata M, Kamatani N, Iwamoto Y, Del Bosque-Plata L, Hayes MG, Cox NJ, Bell GI :
Genetic variants in the calpain-10 gene and the development of type 2 diabetesin the
Japanese population. J Hum Genet. 2005;50:92-8.
2005
Noso S, Ikegami H, Fujisawa T, Kawabata Y, Asano K, Hiromine Y, Tsurumaru M,
Sugihara S, Lee I, Kawasaki E, Awata T, Ogihara T :
Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to
type 1 diabetes.. Diabetes. 54(12):3582-3586 2005.
2004
Awata T, Neda T, Iizuka H, Kurihara S, Ohkubo T, Takata N, Osaki M, Watanabe M,
Nakashima Y, Sawa T, Inukai K, Inoue I, Shibuya M, Mori K, Yoneya S, KatayamaS:
Endothelial nitric oxide synthase gene is associated with diabetic macular
edema in type 2 diabetes. Diabetes Care. 2004;27:2184-90.
2004
Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, Oka Y,
Katayama S, ANGPTL3 is increased in both insulin-deficient and -resistant diabetic
states. Biochem. Biophys. Res. Commun. 317, 1075-1079, 2004
2004
Inukai K, Shewan AM, Pascoe WS, Katayama S, James DE, Oka Y, Carboxy terminus
of glucose transporter GLUT3 contains an apical membrane targeting domain. Mol.
Endocrinol.18, 339-349, 2004
2004
Inoue I, Katayama S : The possibletherapeutic actions of peroxisome proliferator-activated receptor
(PPAR ) agonists, PPAR agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium
(Ca)-antagonists on vascular endothelial cells. Curr Drug Targets Cardiovasc Haematol Disord 4(1):
35-52, 2004
2004
Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, Inaba M, and
Katayama S : Pro12Ala Substitution in Peroxisome Proliferator-Activated Receptor2
Is Associated With Low Adiponectin Concentrations in Young Japanese Men.
Metabolism 53(12) : 1548-1551, 2004.
2004
Katayama S : Tight blood pressure control with ACE inhibitor and /or ARB delays or
improves diabetic nephropathy. Nephrology Frontier 3(3) : 230-231,2004.
2004
Ushiyama M, Morita T, Kuramochi T, Yagi S, Katayama S: Erectile Dysfunction in
Hypertensive Rats Results from Impairment of the Relaxation Evoked by Neurogenic
Carbon Monoxide and Nitric Oxide. Hypertens Res 27(4) : 253-261, 2004.
2004
Nakajima T, Matsunaga T, Kawai S, Hokari S, Inoue I, Katayama S, Nagata A and
Komoda T: Characterization of the epitopes specific for the monoclonal antibody
9F5-3a and quantification of oxidized HDL in human plasma. Ann Clin Biochem
41:309-315, 2004.
